Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT (cosibelimab-ipdl)".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma will present updated pivotal trial data for UNLOXCYT (cosibelimab-ipdl) at the ASCO 2026 Annual Meeting on May 31. The data covers 64 patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) from the CK-301-101 trial. Key results show a 50% objective response rate, including 27% complete responses. After a median follow-up of 31 months, the median duration of response was not yet reached, indicating durable responses. The safety profile was manageable with only 1 patient (2%) experiencing Grade ≥3 immune-related adverse events. This is the second largest prospective study of laCSCC patients treated with PD-(L)1 monotherapy.
Positive development for Sun Pharma's oncology portfolio. The strong efficacy data with durable responses and a manageable safety profile could strengthen UNLOXCYT's market position in advanced skin cancer treatment, though this is a data presentation rather than a new approval or order.